Dynal Biotech ASA Acquires Pel-Freez Clinical Systems and Pel-Freez Biotechnology Beijing

Acquisition Creates Global Leader in HLA Analysis for Transplantation

Dynal Biotech ASA today announced that it has entered into agreements for the acquisition of the businesses of Pel-Freez Clinical Systems, LLC (Milwaukee, Wisconsin, USA) and Pel-Freez Biotechnology (Beijing), Ltd. (Beijing, China), as well as other selected assets of Pel-Freez Diagnostics Inc. Closing of the transaction, which is subject to certain customary conditions is expected to occur prior to the end of October.

"Dynal Biotech has identified the strategic importance of strengthening its positions in North America and in China, and the acquisitions of the Pel-Freez Diagnostics companies represents a step in this direction. The combination with Pel-Freez represents a strong strategic fit in terms of product ranges, industry expertise and infrastructure for the entire Dynal Biotech group. The benefits of this acquisition, particularly to our customer base in the U.S., will be significant. This acquisition will also provide Dynal Biotech with an increased ability to further serve the Chinese market through a new manufacturing, product development, and distribution subsidiary in Beijing." said Jon Hindar, President and CEO of Dynal Biotech.

Peter Maguire, Vice President responsible for Dynal's HLA Business Area, added, "Dynal Biotech has been the world's leading supplier of molecular HLA typing kits for over three years. This acquisition now positions the organization to capitalize on our competence in Transplantation Immunology, with significantly increased focus on the North American market."

"The combination of Pel-Freez and Dynal represents an ideal strategic fit, as the companies' technologies are very complementary as are our relevant geographic strengths. Through this partnership, the combined organization will be able to continue its high levels of technical support and service and develop even more innovative and timely products for our customer base," said Frank Langley, President & CEO of Pel-Freez Clinical Systems, LLC.

About Dynal Biotech ( www.dynalbiotech.com )

Dynal Biotech is the world leader in immunomagnetic separation for isolation and manipulation of biological material, including cells, nucleic acids, proteins and pathogenic micro-organisms. The company has its head offices in Oslo, Norway, and has R&D and manufacturing facilities in Norway and the U.K. Dynal Biotech also has sales subsidiaries in the USA, Germany, France and Australia.

About Pel-Freez ( www.pel-freez.com )

Pel-Freez has been a market leader in the development of molecular and serologic diagnostic products for the global HLA marketplace for over 25 years. With locations in Milwaukee, Wisconsin, USA and Beijing, China, the Pel-Freez companies have prided themselves on innovative and rapid product development along with superior technical support and customer service.

SOURCE: Pel-Freeze Clinical Systems, LLC

CONTACT: Jon Hindar,

President & CEO,

Dynal Biotech ASA,

+47-977-488-29,

[email protected] or

fax, +47-22-50-15-90, or

Frank Langley,

President & CEO,

Pel-Freez Clinical Systems, LLC,

+1-414-214-4001,

[email protected] or

fax, +1-414-357-4518

Web site: http://www.dynalbiotech.com

http://www.pel-freez.com

--Distributed by AsiaNet (www.asianetnews.net)--

• ข่าวthe acquisition
• ข่าวthe transaction
• ข่าวDynal Biotech
• ข่าวPRNewswire
• ข่าวo:heal